search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Immunogenicity and adjuvant effect of the whole cell Pertussis component of the Dutch combined Diphtheria, Tetanus, Pertussis, Poliomyelitis ~ Haemophilus influenzae type b vaccine in infants compared to the old whole cell P vaccine and a new acellular P vaccine component.


- candidate number2538
- NTR NumberNTR946
- ISRCTNISRCTN97785537
- Date ISRCTN created2-mei-2007
- date ISRCTN requested20-apr-2007
- Date Registered NTR4-apr-2007
- Secondary IDsLTR134 
- Public TitleImmunogenicity and adjuvant effect of the whole cell Pertussis component of the Dutch combined Diphtheria, Tetanus, Pertussis, Poliomyelitis ~ Haemophilus influenzae type b vaccine in infants compared to the old whole cell P vaccine and a new acellular P vaccine component.
- Scientific TitleImmunogenicity and adjuvant effect of the whole cell Pertussis component of the Dutch combined Diphtheria, Tetanus, Pertussis, Poliomyelitis ~ Haemophilus influenzae type b vaccine in infants compared to the old whole cell P vaccine and a new acellular P vaccine component.
- ACRONYMaKwK trial
- hypothesisTo compare the immunogenicity of the whole cell versus the acellular pertussis component of the DTP IPV-Hib vaccine as measured by the antibody titers at 11 months before the 4th vaccination and at 12 months.
- Healt Condition(s) or Problem(s) studiedInfectious diseases, Whooping cough, Bordetella pertussis
- Inclusion criteria1. Infants in good general health eligible for the fourth DTP IPV-Hib vaccination.
- Exclusion criteria1. Severe acute illness or fever (>38.5) within two days before vaccination;
2. Present evidence of serious disease(s) demanding medical treatment that might interfere with the results of the study;
3. Known or suspected allergy to any of the vaccine components;
4. Known or suspected immune disorder;
5. History of any neurological disorder, including epilepsy;
6. Previous administration of plasma products (including immunoglobulins);
7. Previous vaccination with any other vaccine than those used in the National Immunisation Programme.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 3-nov-2004
- planned closingdate1-aug-2007
- Target number of participants400
- Interventions4 groups of 75 children aged 11 months:
1. DTwP IPV-Hib primary series and booster (11 months) (n=32);
2. DTwP IPV-Hib primary series and DTaP IPV-Hib booster (Infanrix) (n=79);
3. DTaP IPV-Hib (Infanrix) primary series and booster (n=95);
4. DTaP IPV-Hib (Pediacel) primary series and booster with (n=75) and without (n=75) pneumococcal vaccination (Prevenar).
- Primary outcomeTo compare the immunogenicity of the whole cell versus the acellular pertussis component of the DTP IPV-Hib vaccine as measured by the antibody titers at 11 months before the 4th vaccination and at 12 months. The antibody titers are determined by a twofold serial dilution ELISA.
- Secondary outcomeAntibody titers for all vaccine components are measured at 11 months before vaccination and at 4-8 weeks after the 4th DTP IPV-Hib vaccination. This will also allow to investigate:
1. The effect of the changes in the production process of the Pertussis whole cell component compared to the ‘old’ whole cell component (data on file).
2. The adjuvant effect of the whole cell versus two different acellular Pertussis components in the DTP IPV-Hib vaccine as used in The Netherlands.
3. The immunogenicity and the adjuvant effect of the two different acellular Pertussis components in the DTP IPV-Hib vaccines (Infanrix versus Pediacel) with or without pneumococcal vaccination (Prevenar).
- TimepointsN/A
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESPhD G. Berbers
- CONTACT for SCIENTIFIC QUERIESPhD G. Berbers
- Sponsor/Initiator National Institute for Public Health and the Environment (RIVM)
- Funding
(Source(s) of Monetary or Material Support)
Dutch Ministry of Health, Welfare and Sport
- Publications
- Brief summaryThis study is undertaken to monitor the effects of the changes in the pertussis component of the DTP IPV-Hib vaccine as used in the Dutch National Immunisation Programme. There are 4 study groups consisting of 11 month old children who receive the DTp IPV-Hib vaccine with different pertussis components; a whole cell, 3 component acellular, 5 component acellular and a 5 component acellular with concurrent pneumococcal vaccination. The antibody respons is measured before vaccination at 11 months old and 4-8 weeks after vaccination by ELISAs.
- Main changes (audit trail)
- RECORD4-apr-2007 - 9-dec-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl